Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Subscribe To Our Newsletter & Stay Updated